Prognostic value of decreased long non-coding RNA TUSC7 expression in some solid tumors: a systematic review and meta-analysis
Metrics: PDF 926 views | HTML 1691 views | ?
Na Li1, Meilan Yang1, Ke Shi2 and Wei Li2
1Department of Pathology, The First Affiliated Hospital of Hunan University of Medicine, Huaihua, Hunan Province, China
2Department of Geriatrics, Xiangya Hospital of Central South University, Changsha, Hunan Province, China
Wei Li, email: email@example.com
Keywords: TUSC7, cancer, clinical outcome, prognosis
Received: April 18, 2017 Accepted: May 29, 2017 Published: June 15, 2017
Accumulating evidences indicated that tumor suppressor candidate 7 (TUSC7) is a putatively tumor suppressor gene in various tumors. We carried out current systematic review and meta-analysis to explore the decreased expression of TUSC7 associate with prognostic and clinicopathological characteristic in cancer patients. A literature collection search in the online electronic databases PubMed, Embase, Web of Science, and CNKI was conducted to obtain eligible studies (up to February 20, 2017). A total of nine studies comprise 757 patients were identified and included in present meta-analysis based on the selection and inclusion criteria. Overall, low expression of TUSC7 was associated with significantly unfavorable overall survival (OS) (HR = 2.90, 95% CI: 2.12–3.98, P < 0.001), disease free survival (DFS) (HR = 2.00, 95% CI: 1.49–2.68, P < 0.001) and disease-specific survival (DSS) (HR = 2.57, 95% CI: 1.23–5.39, P = 0.012) in tumors patients. Moreover, we also found that down-regulation of TUSC7 associated with distant metastasis (OR = 2.85, 95% CI: 1.46–5.55, P = 0.002) and larger tumor size (OR = 0.41, 95% CI: 0.23–0.72, P = 0.002). Our meta-analysis demonstrated that cancers patients detected with low TUSC7 expression were more prone to develop distant metastasis. TUSC7 might act as a potentially and promising common prognostic markers in some solid tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.